Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen?

Zenas Biopharma’s obexelimab achieved a statistically significant and clinically meaningful reduction in signs and symptoms of immunoglobulin G4-related disease, but not to the extent shown by Amgen’s Uplizna in its pivotal study. Still, Zenas points to features of its drug that could make it competitive as a maintenance therapy for the rare autoimmune disorder. The…

Read More

Is “inflammaging” inevitable?

Based on a recent study in Nature Aging as summarized in the New York Times: Inflammation is a natural immune response that protects the body from injury or infection. Scientists have long believed that long-term, low-grade inflammation — also known as “inflammaging” — is a universal hallmark of getting older. But this new data raises…

Read More

Aging is Soon to Be a Preventable Disease

For most of human history, cellular aging was treated as biologically fixed, an inevitable accumulation of damage with no meaningful pathway to reversal. That assumption is no longer tenable. The post Aging is Soon to Be a Preventable Disease appeared first on MedCity News.

Read More